BRPI0717023A2 - Tiazol pirazolopirimidina como antagonistas do receptor de crf1 - Google Patents
Tiazol pirazolopirimidina como antagonistas do receptor de crf1Info
- Publication number
- BRPI0717023A2 BRPI0717023A2 BRPI0717023-8A2A BRPI0717023A BRPI0717023A2 BR PI0717023 A2 BRPI0717023 A2 BR PI0717023A2 BR PI0717023 A BRPI0717023 A BR PI0717023A BR PI0717023 A2 BRPI0717023 A2 BR PI0717023A2
- Authority
- BR
- Brazil
- Prior art keywords
- pirazolopyrimidine
- tiazol
- receptor antagonists
- crf1 receptor
- crf1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82626406P | 2006-09-20 | 2006-09-20 | |
| PCT/US2007/078605 WO2008036579A1 (en) | 2006-09-20 | 2007-09-17 | Thiazole pyrazolopyrimidines as crf1 receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0717023A2 true BRPI0717023A2 (pt) | 2014-03-11 |
| BRPI0717023B1 BRPI0717023B1 (pt) | 2019-11-19 |
| BRPI0717023B8 BRPI0717023B8 (pt) | 2021-05-25 |
Family
ID=38924802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0717023A BRPI0717023B8 (pt) | 2006-09-20 | 2007-09-17 | tiazol pirazolopirimidina, seu uso, e composição farmacêutica |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US8030304B2 (pt) |
| EP (1) | EP2094709B1 (pt) |
| JP (1) | JP5161226B2 (pt) |
| KR (1) | KR101088239B1 (pt) |
| CN (1) | CN101516887B (pt) |
| AR (1) | AR062886A1 (pt) |
| AT (1) | ATE481405T1 (pt) |
| AU (1) | AU2007297421B2 (pt) |
| BR (1) | BRPI0717023B8 (pt) |
| CA (1) | CA2663511C (pt) |
| CL (1) | CL2007002693A1 (pt) |
| CR (1) | CR10682A (pt) |
| CY (1) | CY1110854T1 (pt) |
| DE (1) | DE602007009305D1 (pt) |
| DK (1) | DK2094709T3 (pt) |
| EA (1) | EA015179B1 (pt) |
| ES (1) | ES2350282T3 (pt) |
| HK (1) | HK1132505A1 (pt) |
| HR (1) | HRP20100516T1 (pt) |
| IL (1) | IL197614A (pt) |
| MA (1) | MA30798B1 (pt) |
| MX (1) | MX2009003125A (pt) |
| MY (1) | MY146388A (pt) |
| NO (1) | NO20091489L (pt) |
| NZ (1) | NZ575572A (pt) |
| PE (1) | PE20081377A1 (pt) |
| PL (1) | PL2094709T3 (pt) |
| PT (1) | PT2094709E (pt) |
| RS (1) | RS51545B (pt) |
| SI (1) | SI2094709T1 (pt) |
| TN (1) | TN2009000095A1 (pt) |
| TW (1) | TWI402269B (pt) |
| UA (1) | UA96458C2 (pt) |
| WO (1) | WO2008036579A1 (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JP5524221B2 (ja) * | 2008-10-02 | 2014-06-18 | イーライ リリー アンド カンパニー | 合成中間体としてのチアゾリル−ピラゾロピリミジン化合物および関連合成方法 |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP3096756A1 (en) | 2014-01-21 | 2016-11-30 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
| PL236355B1 (pl) * | 2015-04-02 | 2021-01-11 | Celon Pharma Spolka Akcyjna | Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3 |
| CN109906222B (zh) | 2016-09-07 | 2023-08-01 | 加利福尼亚大学董事会 | 减少p-tau并且改善认知的变构促肾上腺皮质激素释放因子受体1(crfr1)拮抗剂 |
| MX2019015318A (es) * | 2017-08-14 | 2020-07-20 | Spruce Biosciences Inc | Antagonistas del receptor del factor liberador de corticotropina. |
| KR20200040761A (ko) | 2017-08-14 | 2020-04-20 | 스프루스 바이오사이언시스 인코포레이티드 | 코티코트로핀 방출 인자 수용체 길항제 |
| JP7427655B2 (ja) * | 2018-04-27 | 2024-02-05 | スプルース バイオサイエンシーズ，インク． | 精巣副腎残存腫瘍および卵巣副腎残存腫瘍を処置するための方法 |
| CN109134481B (zh) * | 2018-08-07 | 2021-05-14 | 中山大学 | 一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用 |
| TWI714231B (zh) * | 2018-09-04 | 2020-12-21 | 美商美國禮來大藥廠 | 2,6-二胺基吡啶化合物 |
| TW202134241A (zh) * | 2019-12-04 | 2021-09-16 | 美商紐羅克里生物科學有限公司 | Ｃｒｆ受體拮抗劑及使用方法 |
| GR1010096B (el) * | 2020-07-02 | 2021-10-08 | Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, | Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης |
| CA3188730A1 (en) * | 2020-08-12 | 2022-02-17 | Christopher Barnes | Methods and compositions for treating polycystic ovary syndrome |
| JP2023540223A (ja) | 2020-08-26 | 2023-09-22 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよび使用方法 |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
| WO2023091684A1 (en) * | 2021-11-19 | 2023-05-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
| WO2023163945A1 (en) * | 2022-02-23 | 2023-08-31 | Crinetics Pharmaceuticals, Inc. | Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0674641T3 (da) | 1992-12-17 | 1999-09-27 | Pfizer | Pyrrolopyrimidiner som CRF-antagonister |
| WO1997029109A1 (en) * | 1996-02-07 | 1997-08-14 | Janssen Pharmaceutica N.V. | Pyrazolopyrimidines as crf receptor antagonists |
| RO121272B1 (ro) | 1996-07-24 | 2007-02-28 | The Du Pont Merck Pharmaceutical Company | Azolotriazine şi pirimidine |
| PL195762B1 (pl) * | 1996-07-24 | 2007-10-31 | Bristol Myers Squibb Pharma Co | Związki [1,5-a]pirazolo-1,3,5-triazynowe, środek farmaceutyczny i zastosowanie związków [1,5-a]pirazolo-1,3,5-triazynowych do wytwarzania leku |
| CZ68199A3 (cs) | 1996-08-28 | 1999-11-17 | Pfizer Inc. | 6,5-Heterobicyklické deriváty, farmaceutická kompozice na jejich bázi a způsob léčení chorob |
| EP1040831A3 (en) * | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
| AU4203500A (en) | 1999-04-06 | 2000-10-23 | Du Pont Pharmaceuticals Company | Pyrazolopyrimidines as crf antagonists |
| AU7737900A (en) | 1999-09-30 | 2001-04-30 | Neurogen Corporation | Amino substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines |
| WO2002072202A1 (en) | 2001-03-13 | 2002-09-19 | Bristol-Myers Squibb Pharma Company | 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands |
| CA2550948A1 (en) | 2003-12-22 | 2005-07-14 | Sb Pharmco Puerto Rico Inc. | Crf receptor antagonists and methods relating thereto |
-
2007
- 2007-09-17 MX MX2009003125A patent/MX2009003125A/es active IP Right Grant
- 2007-09-17 PL PL07842582T patent/PL2094709T3/pl unknown
- 2007-09-17 EP EP07842582A patent/EP2094709B1/en active Active
- 2007-09-17 DE DE602007009305T patent/DE602007009305D1/de active Active
- 2007-09-17 ES ES07842582T patent/ES2350282T3/es active Active
- 2007-09-17 SI SI200730435T patent/SI2094709T1/sl unknown
- 2007-09-17 US US12/377,733 patent/US8030304B2/en active Active
- 2007-09-17 BR BRPI0717023A patent/BRPI0717023B8/pt active IP Right Grant
- 2007-09-17 UA UAA200902216A patent/UA96458C2/ru unknown
- 2007-09-17 CA CA2663511A patent/CA2663511C/en active Active
- 2007-09-17 MY MYPI20091067A patent/MY146388A/en unknown
- 2007-09-17 NZ NZ575572A patent/NZ575572A/en not_active IP Right Cessation
- 2007-09-17 AU AU2007297421A patent/AU2007297421B2/en not_active Ceased
- 2007-09-17 WO PCT/US2007/078605 patent/WO2008036579A1/en active Application Filing
- 2007-09-17 KR KR1020097005602A patent/KR101088239B1/ko not_active IP Right Cessation
- 2007-09-17 EA EA200970303A patent/EA015179B1/ru active IP Right Revival
- 2007-09-17 DK DK07842582.4T patent/DK2094709T3/da active
- 2007-09-17 AT AT07842582T patent/ATE481405T1/de active
- 2007-09-17 PT PT07842582T patent/PT2094709E/pt unknown
- 2007-09-17 CN CN2007800351453A patent/CN101516887B/zh active Active
- 2007-09-17 JP JP2009529316A patent/JP5161226B2/ja active Active
- 2007-09-17 RS RSP-2010/0517A patent/RS51545B/en unknown
- 2007-09-18 AR ARP070104125A patent/AR062886A1/es active IP Right Grant
- 2007-09-20 PE PE2007001271A patent/PE20081377A1/es not_active Application Discontinuation
- 2007-09-20 CL CL200702693A patent/CL2007002693A1/es unknown
- 2007-09-20 TW TW096135177A patent/TWI402269B/zh not_active IP Right Cessation
-
2009
- 2009-03-16 IL IL197614A patent/IL197614A/en active IP Right Grant
- 2009-03-19 TN TN2009000095A patent/TN2009000095A1/fr unknown
- 2009-03-20 CR CR10682A patent/CR10682A/es not_active Application Discontinuation
- 2009-04-16 NO NO20091489A patent/NO20091489L/no not_active Application Discontinuation
- 2009-04-16 MA MA31794A patent/MA30798B1/fr unknown
-
2010
- 2010-01-08 HK HK10100143.4A patent/HK1132505A1/xx active IP Right Revival
- 2010-09-21 HR HR20100516T patent/HRP20100516T1/hr unknown
- 2010-10-21 CY CY20101100946T patent/CY1110854T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0717023A2 (pt) | Tiazol pirazolopirimidina como antagonistas do receptor de crf1 | |
| BRPI0821141A2 (pt) | Derivados de heteroarila como antagonistas do receptor de orexina | |
| BRPI0717937A2 (pt) | Compostos de pirazona como antagonistas do receptor mineralocorticóide | |
| ES2385606T8 (es) | Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina | |
| BRPI0810462A2 (pt) | Derivados de quinolina-carboxamida como antagonistas de p2y12 | |
| BRPI0909157A2 (pt) | compostos heterocíclicos como antagonistas de receptores de adenosina | |
| BRPI0817245A2 (pt) | Derivados e quinolina como antagonistas receptores de 5ht5a | |
| BRPI0910118A2 (pt) | antagonistas de receptores do glucagon | |
| BRPI0919844A2 (pt) | compostos de azaindazol como antagonistas do receptor ccr1 | |
| BRPI0813768A2 (pt) | Derivados de benzazepina úteis como antagonistas de vasopressina | |
| BRPI0913930A2 (pt) | antagonistas de receptores de prostaglandinas d2 | |
| BRPI0917980A2 (pt) | subcanalização com aumento de potência | |
| DK2081951T3 (da) | Progesteron-receptorantagonister | |
| BRPI0814806A2 (pt) | Pirazinas substituídas como antagonistas de cb1 | |
| DK2009992T3 (da) | Il-8 receptor-antagonister | |
| BRPI0718494A2 (pt) | Derivado de fenilsulfamoil benzamida como antagonistas de bradicinina | |
| BRPI0814767A2 (pt) | Derivados de monoamida como antagonistas do receptor de orexina | |
| BRPI0810926A2 (pt) | Antagonista de crig | |
| BRPI0913057A2 (pt) | azetidinas e ciclobutanos como antagonistas de receptor de histamina h3 | |
| BRPI0817061A2 (pt) | Derivados de pirrolidinilalquilisoquinolinona e -isoindolinona como antagonistas de histamina-3 | |
| ATE555111T1 (de) | Chinuclidinol-derivate als muscarinrezeptor- antagonisten | |
| BRPI0918004A2 (pt) | antagonistas de glucagon | |
| CU23857B1 (es) | Nuevos derivados de benzamida como antagonistas de la bradiquinina | |
| BRPI0720078A2 (pt) | 2-aminoquinolinas como antagonistas de receptores de 5-ht(5a) | |
| BRPI0817969A2 (pt) | Aditivos de cimento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/11/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/09/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |